Obesity as a risk factor for chemotherapy-induced peripheral neuropathy in patients with breast cancer undergoing treatment with Paclitaxel
DOI:
https://doi.org/10.11606/issn.2317-0190.v26i3a167069Keywords:
Peripheral Nervous System Diseases, Drug Therapy, Risk Factors, Obesity, RehabilitationAbstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling condition resulting from chemotherapy for cancer. Among the risk factors, the presence of previous neuropathy and low creatinine clearance stands out. Objective: To assess the occurrence of CIPN among breast cancer patients submitted to the use of adjuvant Paclitaxel (TAXOL) and its relationship with obesity. Methods: An observational, retrospective study that evaluated the medical records of breast cancer patients undergoing adjuvant treatment with the use of Paclitaxel in the first half of 2019, collecting data related to CIPN, weight, height and BMI. Results: Among the 70 patients evaluated, 44.3% had a BMI between 25.0 and 29.9 kg / m2, 15.7% between 30.0 and 34.9 kg / m2, 8.6% between 35, 0 and 39.9 Kg / m2, and 1.4% greater than 40.0 Kg / m2. The presence of peripheral neuropathy was documented in 57.14% of the patients. The mean BMI found in patients without neuropathy was 25.05 and in patients with neuropathy it was 29.10 (p = 0.0005). Spearman's correlation between the presence of neuropathy and BMI values showed a positive correlation with r = 0.40 and p = 0.0006. The Relative Risk RR for the occurrence of neuropathy in relation to BMI values was 1,833 for BMI above 25 (95% CI). Conclusion: There is a positive correlation between BMI values and the ocurrence of CIPN in this sample of patients, which suggests that obesity may be a risk factor for the emergence of CIPN.
Downloads
References
Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479-94. DOI: http://dx.doi.org/10.1016/j.ejca.2009.12.008
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-67. DOI: http://dx.doi.org/10.1200/JCO.2013.54.0914
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461-70. DOI: http://dx.doi.org/10.1016/j.pain.2014.09.020
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;(3):CD005228. DOI: http://dx.doi.org/10.1002/14651858.CD005228.pub4
Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15(29):3081-94. DOI: http://dx.doi.org/10.2174/092986708786848569
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33(1):15-49. DOI: http://dx.doi.org/10.1053/j.seminoncol.2005.12.010
Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E. Chemotherapy-induced neuropathy. Curr Treat Options Neurol. 2011;13(2):180-90. DOI: http://dx.doi.org/10.1007/s11940-010-0108-3
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14 Suppl 4(Suppl 4):iv45-54. DOI: http://dx.doi.org/10.1093/neuonc/nos203
Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327-33. DOI: http://dx.doi.org/10.1007/s10549-016-3939-0
Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran. Asian Pac J Cancer Prev. 2015;16(17):7603-6. DOI: http://dx.doi.org/10.7314/apjcp.2015.16.17.7603
U.S. Department of Health & Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 published: november 27, 2017 [text on the Internet]. Washington, D.C.: HHS [cited 2019 Aug 05]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
Cox-Martin E, Trahan LH, Cox MG, Dougherty PM, Lai EA, Novy DM. Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2017;25(6):1873-1879. DOI: http://dx.doi.org/10.1007/s00520-017-3571-5
Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, et al. BMI, Lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study. J Natl Cancer Inst. 2016;109(2):djw206. DOI: http://dx.doi.org/10.1093/jnci/djw206
